October 29, 2020 | Blog
2020 USA Election & Drug Pricing Outlook
An analysis of the key drug pricing proposals in the 2020 USA Election in terms of political focus, party priorities, implementation feasibility, and potential risk to biopharma.
Annabelle Brough
Senior Analyst
Annabelle Brough is a Senior Analyst at CBPartners
Connect with Annabelle Brough
Published Articles
September 7, 2020 | Research posters
ISPOR Asia-Pacific 2020: Dancing with the Dragon – Considerations and Learnings in the 2019 China NRDL Negotiations
A research poster that aims to evaluate the outcomes of the 2019 NRDL negotiations involving PDx inhibitors and DAA products.
June 2, 2020 | Blog
2019 NRDL: Insights for Future Pricing Negotiations in China
The 2019 NRDL update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas. CBPartners' blog post examines how these learnings can help shape future NRDL negotiations.
January 29, 2020 | Blog
Strategic Thinking: The Global Drug Launch Pricing Dilemma
Several factors contribute towards manufacturers seeking new ways to develop global drug pricing strategies. Product launches vary based on geography; when comparing the USA to EU, access outcomes can vary significantly based on whether or not the pivotal trial design has been optimized for each region.
November 19, 2019 | Blog
The Cancer Drugs Fund: Paving the Way for Earlier and More Sustainable Access to Promising New Drugs
In 2011, The Cancer Drugs Fund (CDF) was launched to help patients in England access cancer drugs that had been rejected by the NHS. CBPartners' European Center of Excellence discusses the benefits of early engagement with NICE for both manufacturers and patients alike.
